17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
Severe Pain
Mundipharma CVASmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Severe Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naloxone, (+)- Mundipharma CVA | D | |
Targinact® Mundipharma CVA | D |
Same molecule, other indications
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →